Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

NRAS mutant melanoma: Targeted therapy, are we there yet?

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Combination strategies of immunotherapy in breast cancer

ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Cardiac events in stage III NSCLC treated in daily clinical practice

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer

Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC

Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer